Antibodies Current Events | Antibodies News | 3
|
| Page
3 of
17 |
335 Results |
|
|
|
Sort By:
Page Views | Date |
'Nanobodies' herald a new era in cancer therapy
Cancer, along with heart and vascular disease, is the major cause of death in the Western world. The first generation of anti-cancer drugs has already saved many lives, but because these medicines are non-specific they also often have severe side effects. Researchers at VIB (the Flanders Interuniversity Institute for Biotechnology) are now... view more... (2004-05-12)
Rheumatoid arthritis drug linked to serious infections and cancers
A new meta-analysis of many previous studies of TNF- (tumor necrosis factor) blocking antibodies for treatment of rheumatoid arthritis has confirmed a previously discovered increased risk for serious infection and has found that cancer also is a potential risk associated with the drugs. view more (2006-05-17)
Which is more accurate, serology test or C14-urea breath test?
Serology and C14-UBT are the most commonly used non-invasive tests of H. pylori infection. The diagnostic characteristics of the tests depend also on the prevalence of H. pylori infection in the population tested. view more (2008-09-10)
Xerion Pharmaceuticals and Arius Research sign colon cancer collaboration
Martinsried, Germany and Cambridge, Massachusetts, USA - October 15, 2002"¦Xerion Pharmaceuticals and ARIUS Research Inc. of Canada announced today that they would combine their respective strengths in functional proteomics and antibody discovery to jointly develop products for cancer therapy. Xerion will take four antibodies from ARIUS'... view more... (2002-10-15)
Vaccine prevents prion disease in mice
An oral vaccine can prevent mice from developing a brain disease similar to mad cow disease. view more (2007-05-04)
Affibody and Mabtech initiates research collaboration
Today, Affibody AB and Mabtech AB announce the initiation of a research collaboration with the aim to develop diagnostic kits for the research diagnostics market. The kits will be used for detection of disease-related proteins. Under the agreement, Affibody will supply proprietary affinity ligands - Affibody molecules, to Mabtech who will develop... view more... (2004-04-01)
A natural approach for HIV vaccine
For 25 years, researchers have tried and failed to develop an HIV vaccine, primarily by focusing on a small number of engineered "super antibodies" to fend off the virus before it takes hold. view more (2009-03-16)
Cancer vaccine one step closer
Andreea Ioan-Facsinay from Leiden University Medical Center has attached proteins from tumour cells to antibodies. With these she treated immune cells from a mouse. These treated cells were used to make a vaccine, which was shown to be effective in animal experiments. If the follow-up research is successful, vaccines against cancer will become... view more... (2003-02-14)
UT Southwestern tests new asthma medicine targeting vulnerable inner-city children
UT Southwestern Medical Center is one of a handful of top research institutions evaluating a promising new medication researchers hope can reduce the severity and frequency of asthma attacks in inner-city children, a population known to have a high prevalence of severe asthma. view more (2006-10-19)
Study offers insights into failed HIV-1 vaccine trial
Following the disbandment of the STEP trial to test the efficacy of the Merck HIV-1 vaccine candidate in 2007, the leading explanation for why the vaccine was ineffective - and may have even increased susceptibility to acquiring the virus - centered on the hypothesis that high levels of baseline Ad5-specific neutralizing antibodies may have... view more... (2009-07-21)
Oxford Biomedica Plc And Arius Research Inc. Sign Collaborative Programme In Tumour Immunotherapy
Oxford, United Kingdom and Toronto, Canada - 25 July 2002. Oxford BioMedica plc (LSE:OXB) ("BioMedica") and ARIUS Research Inc. ("ARIUS) of Canada announced today a research and development collaboration to search for targets and develop novel products to treat cancer. Under the collaboration ARIUS will supply BioMedica with a... view more... (2002-07-25)
Unexpected finding opens up new way to stop autoimmune diseases and transplant rejection
After several years of battling recurring infections, the last thing a patient and her doctors ever expected was that the cause of her problems might actually help millions live longer, more active lives. view more (2009-01-23)
Princeton team's analysis of flu virus could lead to better vaccines
A team of Princeton University scientists may have found a better way to make a vaccine against the flu virus. view more (2009-05-13)
Lombardi research: Monoclonal antibodies primed to become potent immune weapons against cancer
New research suggests that monoclonal antibody therapy of cancer can be improved to be much more powerful than it is today, says a researcher at Georgetown University Medical Center's Lombardi Comprehensive Cancer Center in the March 21 issue of the Lancet. view more (2009-03-20)
Aetiology of congenital heart disease explained
Researchers at Karolinska Institutet have identified the mechanisms behind the serious, congenital heart condition that can sometimes develop in children of women with a rheumatic disease. view more (2005-02-07)
Avian influenza survivors' antibodies effective at neutralising H5N1 strain
Adults who have recovered from the potentially deadly H5N1 strain of avian influenza may hold the key to future treatments for the virus, according to an international team of researchers. view more (2007-05-29)
Testing for insulin without the pitter-patter of little feet
In the January issue of Clinical Biochemistry, scientists and physicians with the Physicians Committee for Responsible Medicine (PCRM) outline the method used to develop a cruelty-free ELISA for human insulin that uses monoclonal antibodies produced by cells cultured in an animal-serum-free medium. view more (2007-01-31)
Prodrug could help curb skin toxicity related to EGFR-inhibiting cancer drugs
There may be a way around the harsh skin toxicity associated with a widely used cancer drug, according to a study published online this week in Cancer Biology and Therapy by researchers from City of Hope and the Kimmel Cancer at Jefferson. view more (2009-09-02)
What is potentially pathogenic role of anti-tTG IgA in the development of celiac disease?
The recent detection of antibodies in celiac patients specific for deamidated gliadin peptides (DGP), the product of tTG binding to gliadin peptides, provides an opportunity to address the correlation between the production of anti-tTG IgA and the antibodies against DGP in celiac patients. view more (2009-02-23)
MIT: Extending the shelf life of antibody drugs
A new computer model developed at MIT can help solve a problem that has plagued drug companies trying to develop promising new treatments made of antibodies: Such drugs have a relatively short shelf life because they tend to clump together, rendering them ineffective. view more (2009-06-30)
|
|
| Page
3 of
17 |
335 Results |
|
|
|
Sort By:
Page Views | Date |
|
